Canaccord Genuity reiterated their buy rating on shares of TiGenix – American Depositary Shares (NASDAQ:TIG) in a report published on Monday, December 18th. The firm currently has a $50.00 price target on the stock.
Several other equities analysts have also commented on the stock. BidaskClub lowered shares of TiGenix – American Depositary Shares from a sell rating to a strong sell rating in a research note on Saturday, December 9th. Zacks Investment Research lowered shares of TiGenix – American Depositary Shares from a hold rating to a sell rating in a research note on Saturday, October 21st.
Shares of TiGenix – American Depositary Shares (NASDAQ:TIG) traded up $0.27 during trading on Monday, reaching $41.35. 16,798 shares of the company’s stock traded hands, compared to its average volume of 17,399. TiGenix – American Depositary Shares has a one year low of $14.30 and a one year high of $41.69. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.36 and a current ratio of 1.37.
A hedge fund recently bought a new stake in TiGenix – American Depositary Shares stock. EAM Investors LLC bought a new position in shares of TiGenix – American Depositary Shares (NASDAQ:TIG) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 155,886 shares of the company’s stock, valued at approximately $3,517,000. EAM Investors LLC owned about 1.20% of TiGenix – American Depositary Shares at the end of the most recent quarter. 5.31% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “TiGenix – American Depositary Shares (TIG) Stock Rating Reaffirmed by Canaccord Genuity” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/13/tigenixs-tig-buy-rating-reaffirmed-at-canaccord-genuity.html.
About TiGenix – American Depositary Shares
TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.
Receive News & Ratings for TiGenix - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TiGenix - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.